预计到2035年,全球将有一半以上的人口超重或肥胖
肥胖症已经蔓延全球。胰高血糖素样肽1(GLP-1)激动剂是一种有效的减肥药物,但不应是解决肥胖问题的唯一答案。通过采用高质量的全面策略,我们可以改变体重管理方法,从短期解决方案转向追求终身幸福。
Chief Executive Officer and Founder of Transcarent. Former Executive Chairman, Chief Executive Officer and Founder of Livongo Health, the first at-scale consumer digital health company to empower people with chronic conditions to live better and healthier lives using data science. Visionary leader and entrepreneur, previously ran two other public companies that changed the way health care is delivered. Former Chief Executive Officer of Allscripts. Prior to Allscripts, Chief Executive Officer of Enterprise Systems. Before entering healthcare, President and Chief Operating Officer of CCC Information Systems,. Founding Partner of 7wireVentures. Author of On Our Terms: Empowering the New Health Consumer, proposing new solutions to address the chronic condition epidemic facing the country. A strong proponent of philanthropy. Recipient Robert F. Kennedy Human Rights Ripple of Hope Award (2019). Life Director of the Illinois Chapter of JDRF, a leading organization advancing life-changing breakthroughs for Type 1 Diabetes.
肥胖症已经蔓延全球。胰高血糖素样肽1(GLP-1)激动剂是一种有效的减肥药物,但不应是解决肥胖问题的唯一答案。通过采用高质量的全面策略,我们可以改变体重管理方法,从短期解决方案转向追求终身幸福。
While glucagon-like peptide 1 agonists (GLP-1) have been identified as an effective weight-loss drug, they should only be part of the solution.